-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Like the toughest of weeds, glioblastomas almost always rebound -- usually within a few months of a patient's original brain tumor being surgically remov.
One of the challenges in treating the disease is that surgeons cannot always remove every tumor or glioma stem cell that may remain in the bra.
"One of the hallmarks of glioblastoma is that the tumor cells are so aggressive that they infiltrate the surrounding tiss.
But Professor Hu's Cell-Inspired Personalized Therapy (CIPT) lab has developed a powerful immune-boosting postoperative treatment that could change the odds of developing glioblastoma patien.
"It offers hope for preventing glioblastoma from recurring," Hu sa.
Hu's lab has developed a hydrogel that can be injected into the brain cavity left behind after a tumor is remov.
The hydrogels are filled with nanoparticles designed to enter and reprogram specific types of immune cells called macrophag.
"We want to take these macrophages and turn them from enemies to allies," Hu sa.
To do this, the nanoparticles can target macrophages to a glycoprotein called CD133, which is a hallmark of cancer stem cel.
If effective in humans, hydrogel therapy could eliminate the need for postoperative chemotherapy or radiotherapy, reduce toxic side effects, and improve patient outcom.
Hu's next step is to test the hydrogel in a larger animal model and monitor its long-term efficacy and toxicity over the 4- to 6-month period of his previous stu.
"We still have a lot of work to do before it can be used in the clinic, but we are confident that this is a very promising approach that could give glioblastoma patients new hope in their post-surgery recovery," Hu sa.
He noted that while Hu's team initially focused on glioblastoma, the treatment could also be applied to other aggressive solid tumors, including breast canc.
Earlier this year, Hu, in collaboration with UW School of Pharmacy professor Seungpyo Hong and colleagues in the School of Public Health, published results from another cancer-fighting g.
